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© 2015 Goláň et al. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0)  
License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further 
permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on 
how to request permission may be found at: http://www.dovepress.com/permissions.php
Drug Design, Development and Therapy 2015:9 3435–3444
Drug Design, Development and Therapy Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
3435
O r i g i n a l  r e s e a r c h
open access to scientific and medical research
Open access Full Text article
http://dx.doi.org/10.2147/DDDT.S80928
Evaluation of the efficacy and safety of three 
dosing regimens of agalsidase alfa enzyme 
replacement therapy in adults with Fabry disease
Lubor Goláň1
Ozlem goker-alpan2
Myrl holida3
ikka Kantola4
Mariusz Klopotowski5
Johanna Kuusisto6
aleš linhart1
Jacek Musial7
Kathleen nicholls8
Derlis gonzalez-rodriguez9
reena sharma10
Bojan Vujkovac11
Peter chang12
anna Wijatyk12
1First Faculty of Medicine, Department of 
cardiovascular Medicine, charles University, 
Prague, czech republic; 2lysosomal research 
and Treatment Unit, Fairfax, Va, Usa; 3stead 
Family Department of Pediatrics, Division 
of Medical genetics, University of iowa 
hospitals and clinics, iowa city, ia, Usa; 
4Division of Medicine, Turku University 
hospital, Turku, Finland; 5institute of 
cardiology, Warsaw, Poland; 6Department of 
Medicine, center for Medicine and clinical 
research, University of eastern Finland 
and Kuopio University hospital, Kuopio, 
Finland; 7Department of internal Medicine, 
Jagiellonian University Medical college, 
Krakow, Poland; 8Department of nephrology, 
royal Melbourne hospital and the University 
of Melbourne, Vic, australia; 9instituto 
Privado de hematologia e investigacion 
clinica (iPhic), asuncion, Paraguay; 10salford 
royal nhs Foundation Trust, salford, UK; 
11general hospital slovenj gradec, slovenj 
gradec, slovenia; 12shire, lexington, Ma, Usa
Purpose: Efficacy and safety of agalsidase alfa at 0.2 mg/kg weekly were compared with 0.2 mg/kg 
every other week (EOW). Exploratory analyses were performed for 0.4 mg/kg weekly.
Patients and methods: This was a 53-week, Phase III/IV, multicenter, open-label study 
(NCT01124643) in treatment-naïve adults ($18 years) with Fabry disease. Inclusion criteria were 
left ventricular hypertrophy at baseline, defined as left ventricular mass indexed to height .50 g/m2.7 
for males and .47 g/m2.7 for females. Primary endpoint was reduction of left ventricular mass 
indexed to height as assessed by echocardiography. Secondary endpoints included cardiac (peak 
oxygen consumption, 6-minute walk test, Minnesota Living with Heart Failure Questionnaire, 
New York Heart Association classification), renal (Modification of Diet in Renal Disease, esti-
mated glomerular filtration rate), and biomarker (plasma globotriaosylceramide) assessments. 
Safety endpoints were adverse events and anti–agalsidase alfa antibodies.
Results: Twenty patients were randomized to 0.2 mg/kg EOW (mean age, 50.3 years; 70% male), 
19 to 0.2 mg/kg weekly (51.8 years; 53% male), and 5 to 0.4 mg/kg weekly (49.4 years; 40% male). 
The mean change in left ventricular mass indexed to height by Week 53 in the 0.2-mg/kg EOW 
and weekly groups was 3.2 g/m2.7 and 0.5 g/m2.7, with no significant difference between groups. No 
clinically meaningful changes by Week 53 were found within or between the 0.2-mg/kg groups for 
peak oxygen consumption, 6-minute walk test, or Minnesota Living with Heart Failure Question-
naire. Two patients in each group improved by $1 New York Heart Association classi fication. 
No significant differences were found between 0.2 mg/kg EOW and weekly for mean change in 
estimated glomerular filtration rate (−1.21 mL/min/1.73 m2 vs −3.32 mL/min/1.73 m2) or plasma 
globotriaosylceramide (−1.05 nmol/mL vs −2.13 nmol/mL), respectively. Infusion-related adverse 
events were experienced by 25% and 21% in the 0.2-mg/kg EOW and weekly groups. Tachycardia, 
fatigue, and hypotension were experienced by two or more patients overall. Anti–agalsidase alfa 
antibodies were detected in 11.4% of patients and neutralizing antibodies in 6.8%. Infusion-related 
reactions did not appear to be correlated with antibody status.
Conclusion: No efficacy or safety differences were found when the approved EOW dosage 
of agalsidase alfa was increased to weekly administration. Exploratory analyses for 0.4 mg/kg 
weekly showed similar results.
Keywords: adverse events, exercise tolerance, left ventricular hypertrophy, lysosomal storage 
disorder, quality of life, renal function
Introduction
Fabry disease (FD) is a rare, X-linked glycosphingolipid storage disorder caused by 
mutations in the GLA gene (location chromosome Xq22.1).1 The resulting functional 
deficiency in the alpha-galactosidase A enzyme (EC 3.2.1.22) leads to accumulation of 
glycosphingolipids, especially globotriaosylceramide (Gb
3
), in lysosomes.2 The effects 
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of Gb
3
 accumulation are progressive; it occurs throughout 
the body and affects many tissues and organs, with symptom 
severity in both male and female patients increasing with 
age. Symptoms of FD include debilitating neuropathic pain, 
proteinuria and progressive renal failure, and cerebrovascular 
and cardiovascular diseases, particularly hypertrophic car-
diomyopathy, ultimately leading to premature mortality.3–12 
FD-associated cardiomyopathy occurs in both classic and 
cardiac variant clinical types and is characterized by progres-
sive left ventricular hypertrophy (LVH), which is reflected 
by a progressive increase in left ventricular mass indexed to 
height (LVMI, g/m2.7).13 In females, the age of onset tends 
to be later and the rate of progression is slower.10
Agalsidase alfa has been approved for the treatment of 
FD in numerous countries for over 10 years. A number of 
studies have evaluated the efficacy of agalsidase alfa in the 
treatment of both children and adult patients with FD.14–20 
A previous short-term clinical study (NCT00097890) found 
similar safety, tolerability, and pharmacodynamic response 
of the approved agalsidase alfa dosing regimen of 0.2 mg/kg 
every other week (EOW) compared with regimens ranging 
from 0.1 mg/kg to 0.4 mg/kg weekly or EOW.21 In order to 
fulfill a European postmarketing commitment, the current 
study was designed to evaluate the efficacy and safety of 
two agalsidase alfa dosing regimens (0.2 mg/kg EOW and 
0.2 mg/kg weekly) in a specific population of adults with 
FD and LVH. Additional exploratory analyses were also 
undertaken with a dose of 0.4 mg/kg weekly.
Materials and methods
study design and patients
This was a 1-year, Phase III/IV, multicenter, randomized, 
three-arm, open-label study. Eligible patients included 
treatment-naïve adults ($18 years) with a confirmed diagnosis 
of FD (biochemical testing and/or genotyping for males, geno-
typing for females) and LVH defined as .50 g/m2.7 for males 
and .47 g/m2.7 for females,13 determined by echocardiogra-
phy. Patients were excluded if they had documented New 
York Heart Association (NYHA) functional Class IV heart 
failure symptoms, clinically significant systemic hypertension 
(untreated resting blood pressure .160/110 mmHg or poorly 
controlled hypertension defined by a blood pressure .150/100, 
while receiving antihypertensive medication), hemodynami-
cally significant valvular stenosis or regurgitation, morbid 
obesity (body mass index .39 kg/m2), and known autosomal 
dominant sarcoplasmic contractile protein gene mutation.
Patients provided signed informed consent forms that were 
approved by the treating centers’ Institutional Review Board/
Independent Ethics Committee and were randomized in an 
approximate 4:4:1 ratio to one of three agalsidase alfa (Repla-
gal®; Shire, Lexington, MA, USA) dosing regimens administered 
as an IV infusion: 0.2 mg/kg EOW, main comparator 0.2 mg/kg 
weekly (both administered over 40 minutes), exploratory dose 
of 0.4 mg/kg weekly (administered over 80 minutes).
Efficacy and safety outcomes
The primary efficacy endpoint was absolute change in LVMI 
from baseline to Week 53. Echocardiography using M-mode 
measurements guided by 2D imaging was standardized 
across the study sites. Echocardiograms were read by a single 
reader in a central laboratory, who was blinded to treatment 
and clinical information, and LVM was calculated using a 
published formula22 before being indexed to height (g/m2.7).13 
The secondary efficacy endpoints were changes from baseline 
to Week 53 in peak oxygen consumption (peak VO
2
), evalu-
ated using the standard exponential exercise protocol;23 the 
6-minute walk test (6MWT);24 the Minnesota Living with Heart 
Failure Questionnaire;25 NYHA heart failure classification;26 
estimated glomerular filtration rate (eGFR), tested in a cen-
tralized laboratory and calculated using the four-variable 
formula for Modification of Diet in Renal Disease eGFR, 
which takes into account the serum creatinine value (mg/dL) 
and patient age, sex, and race;27 proteinuria/albuminuria, 
using the urine albumin/creatinine ratio (A/Cr); and fasting 
plasma Gb
3
.28 An additional subset analysis of eGFR stratified 
by baseline chronic kidney disease (CKD) stage was per-
formed: Stage 1A, $130 mL/min/1.73 m2 (hyperfiltrators); 
Stage 1B, 90 mL/min/1.73 m2 to ,130 mL/min/1.73 m2; 
Stage 2, 60 mL/min/1.73 m2 to ,90 mL/min/1.73 m2; Stage 3, 
30 mL/min/1.73 m2 to ,60 mL/min/1.73 m2; Stage 4/5, 
0 to ,30 mL/min/1.73 m2.
Safety endpoints included treatment-emergent adverse 
events ([AEs] that occurred on or after the first agalsidase 
alfa infusion); use of concomitant medications; and changes 
in laboratory test results, vital signs, and electrocardiogram 
results. Blood samples for anti–agalsidase alfa antibody 
determination were screened using an enzyme-linked immu-
nosorbent assay and all positive samples were confirmed by 
a titration assay. Positive samples were isotyped and tested 
for neutralizing enzyme activity using an in vitro assay. 
Absorbance ratios $2.0 relative to baseline were considered 
antibody positive if absolute absorbance was .0.04.
Primary and secondary efficacy endpoints and safety were 
compared in the two 0.2-mg/kg treatment groups, whereas 
the 0.4-mg/kg treatment group was included for exploratory 
purposes only.
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statistical analyses
Statistical analyses were performed using SAS® statistical 
software version 9.3 (SAS Institute Inc., Cary, NC, USA). 
A two-sided, two-sample t-test, assuming a 5% Type I 
error rate and a 5-g/m2.7 common standard deviation, was 
performed to determine the sample size that would provide 
80% power to detect a 5-g/m2.7 treatment difference in the 
primary efficacy endpoint (mean change from baseline in 
LVM)29 between the two 0.2-mg/kg dose groups. A 10% 
dropout rate was also assumed; thus, a total of 38 patients 
were required for the two 0.2-mg/kg groups, and the addition 
of five patients for the exploratory 0.4-mg/kg group made 
the total required for enrollment 43 patients.
Baseline demographics and clinical characteristics were 
summarized using descriptive statistics. Where comparisons 
were made between the two 0.2-mg/kg treatment groups, the 
two-sample t-test was used to analyze continuous baseline 
parameters, and the exact Cochran-Mantel-Haenszel general 
association test and row means score test were used to ana-
lyze nominal-scaled and ordinal-scaled categorical baseline 
parameters, respectively.
The primary efficacy endpoint was analyzed using a 
repeated-measures analysis of variance model with baseline 
LVMI as the covariate, treatment, time, and treatment-by-
time interaction as fixed effects, and patients nested within-
treatment group as a random effect. The treatment effect 
and comparison P-values were estimated from the indicated 
statistical model for comparison of changes between the 
two 0.2-mg/kg treatment groups. No treatment comparisons 
between each of the two 0.2-mg/kg groups versus the 0.4-mg/kg 
weekly group were performed.
Least squares means (LSM) for changes from baseline 
for each of the two 0.2-mg/kg groups, the differences in 
LSMs between the two groups, and the associated two-sided 
95.005% (due to multiplicity adjustment) confidence inter-
vals (CI) were estimated. Other continuous efficacy endpoints 
were analyzed using a similar approach.
With a few exceptions, P-values #0.05 were consid-
ered to indicate statistical significance (ie, 95% CIs were 
estimated). The exceptions were LVMI, eGFR, and plasma 
Gb
3
, where P-values #0.04995 were used (ie, 95.005% CIs 
were estimated) as the significance level due to multiplic-
ity adjustment from performing a planned interim analysis. 
As each of the efficacy endpoints was analyzed using a 
repeated-measures analysis of variance model with baseline 
endpoint as the covariate, no imputation methods were used 
in the analyses.
Results
Patient population
Among the 65 patients, 21 failed screening, mostly due to 
having a baseline LVMI below the level of the inclusion 
criterion. The remaining 44 patients were randomized to 
treatment (Figure 1). The demographic and baseline clinical 
characteristics are summarized in Table 1; briefly, the 0.2-mg/kg 
EOW group contained more males (n=14/20; 70%) than the 
Figure 1 Patient disposition.
Abbreviations: icF, informed consent form; lVMi, left ventricular mass indexed to height.
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0.2-mg/kg weekly group (n=10/19; 52.6%) and also a higher 
percentage of patients .45 years of age (75.0% vs 68.4%). 
Mean age was similar across the three treatment groups. Cardiac 
status in terms of NYHA classification appeared to be more 
advanced for the 0.2-mg/kg EOW group compared with the 
0.2-mg/kg weekly group, with more patients classified as Class II 
or III (Table 1). Three patients (15%) in the 0.2-mg/kg EOW 
group were discontinued (one had participation terminated by 
the investigator, one was discontinued due to noncompliance, 
and one suffered fatal cardiac arrest, deemed unrelated to the 
study drug). One patient (5.3%) in the 0.2-mg/kg weekly group 
withdrew consent, and all five patients (100%) randomized to 
the 0.4-mg/kg weekly group completed the study.
Efficacy outcomes
The primary efficacy endpoint, LVMI, remained relatively 
stable over the study period in both 0.2-mg/kg dose groups 
(Table 2), as reflected by mean overall changes from baseline 
at Week 53 of 3.2 g/m2.7 (3.9%) for the 0.2-mg/kg EOW 
group and 0.5 g/m2.7 (3.4%) for the 0.2-mg/kg weekly group. 
The mean change in LVMI in the exploratory 0.4-mg/kg 
weekly group was −10.3 g/m2.7 (−9.3%). When assessed by 
sex, mean changes from baseline within each of the three 
dose groups for males and females were not statistically 
significant as the 95% CIs contained zero (Table 2). The 
difference in LVMI mean change from baseline between 
the two 0.2-mg/kg groups was not statistically significant 
(LSM difference −2.20g/m2.7; standard error 4.93; 95.005% 
CI: −12.26, 7.85; unadjusted P-value =0.6585).
No statistically significant differences in changes from 
baseline to Week 53 between the 0.2-mg/kg EOW and 
weekly groups were found for exercise tolerance (6MWT 
and peak VO
2
), although an increase in mean distance walked 
in the 6MWT of 37.9 m (95% CI: 2.9, 73.0) was found for 
the 0.2-mg/kg weekly group (Table 3). A slight decrease in 
peak VO
2 
was noted in the group receiving 0.2 mg/kg EOW 
(change: −2.0 mL/kg/min, 95% CI: −3.91, −0.16; Table 3).
Regarding quality of life, the mean Minnesota Living with 
Heart Failure Questionnaire summary score at baseline for 
the 0.2-mg/kg EOW group was 37.0 compared with 21.1 for 
the 0.2-mg/kg weekly group, possibly suggesting a greater 
impact of disease burden at the start in this group (Table 3). 
By Week 53, however, the mean change within each group 
was not considered clinically meaningful, nor was it consid-
ered statistically significant when compared between the two 
groups. No significant or clinically meaningful changes from 
baseline to Week 53 in exercise tolerance or quality of life 
were noted for the 0.4-mg/kg weekly group (Table 3).
An improvement of one class or higher in the NYHA clas-
sification at Week 53 for patients who had NYHA Class II or III 
at baseline plus a Week 53 evaluation (baseline: nine mild and 
two moderate in the 0.2-mg/kg EOW group, and baseline: eight 
mild in the 0.2-mg/kg weekly group) was seen in two patients 
in the 0.2-mg/kg EOW group (18.2%) and two in the 0.2-mg/kg 
Table 1 Baseline demographics and clinical characteristics
Variable 0.2 mg/kg  
EOW
0.2 mg/kg 
weekly
0.4 mg/kg  
weekly
P-value (0.2 mg/kg, 
EOW vs weekly)
number of patients 20 19 5
age, years
Mean (sD) 50.3 (7.2) 51.8 (11.4) 49.4 (9.8) 0.6418
Median (range) 50.5 (37.0–63.0) 49.6 (31.0–70.0) 52.7 (33.0–57.0)
age group, n (%)
.45 years old 15 (75.0) 13 (68.4) 4 (80.0) 0.7311
sex 
Male, n (%) 14 (70.0) 10 (52.6) 2 (40.0) 0.3332
Time since FD diagnosis, mean years (sD) 2.1 (2.38) 1.57 (2.41) 8.13 (10.66)
NYHA classification, n (%) 0.0717
class i (asymptomatic) 6 (30.0) 10 (52.6) 2 (40.0)
class ii (mild) 11 (55.0) 9 (47.4) 2 (40.0)
class iii (moderate) 3 (15.0) 0 1 (20.0)
class iV (severe) 0 0 0
Blood pressure, mmhg
systolic, mean (sD) 121.2 (16.7) 122.2 (14.2) 119.8 (1.0)
Diastolic, mean (sD) 75.7 (9.6) 72.7 (11.1) 68.4 (4.4)
concomitant medication, n (%)
aceis 10 (50.0) 8 (42.1) –
arBs 2 (10.0) 7 (36.8) –
Note: concomitant medication data is not provided for the exploratory 0.4 mg/kg weekly group as shown by dashes. 
Abbreviations: aceis, angiotensin-converting enzyme inhibitors; arBs, angiotensin receptor blockers; eOW, every other week; FD, Fabry disease; nYha, new York 
heart association; sD, standard deviation.
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Table 2 changes from baseline to Week 53 in lVMi
Parameter 0.2-mg/kg EOW  
mean values
0.2-mg/kg weekly  
mean values
0.4-mg/kg weekly  
mean values
(0.2 mg/kg weekly minus EOW)
LSM difference 95.005% CI Unadjusted P-value
lVMi, g/m2.7
Bl (n) 76.1 (20) 82.6 (19) 99.3 (5) −2.20 −12.26, 7.85 0.6585
Wk 53 (n) 79.8 (15)a 79.3 (18)b 89.0 (5)
change 3.2 0.5 −10.3
% change 3.9 3.4 −9.3
95% ci −3.71, 10.14 −7.35, 8.32 −24.9, 4.3
Males
Bl (n) 80.1 (14) 84.3 (10) 122.2 (2) −7.6 −23.24, 8.01 0.3184
Wk 53 (n) 87.4 (10) 83.3 (10) 105.5 (2)
change 7.2 −1.0 −16.7
% change 9.5 1.1 −11.5
95% ci −1.81, 16.21 −14.95, 12.94 −171.76, 138.28
Females
Bl (n) 66.7 (6) 80.6 (9) 84.0 (3) 7.85 −2.55, 18.25 0.1238
Wk 53 (n) 64.7 (5) 74.3 (8) 78.0 (3)
change −4.8 2.4 −6.0
% change −7.3 6.3 −7.7
95% ci −15.24, 5.74 −6.28, 10.99 −24.83, 12.93
Notes: change and % change are calculated based on mean values. all cis are calculated based on the mean (descriptive or least squares). aThree patients discontinued 
before Week 53 and two did not have the required images for lVMi assessment. bOne patient discontinued before Week 53.
Abbreviations: BL, baseline; CI, confidence interval; EOW, every other week; LSM, least squares mean; LVMI, left ventricular mass indexed to height, Wk, week.
Table 3 changes from baseline to Week 53 in exercise tolerance (peak VO2 and 6MWT) and quality of life (MlhF-Q summary 
score)
Parameter 0.2-mg/kg EOW  
mean values
0.2-mg/kg weekly  
mean values
0.4-mg/kg weekly  
mean values
0.2 mg/kg weekly minus EOW
LSM difference 95% CI P-value
Peak VO2, ml/min/kg
Bl (n) 20.2 (19) 22.6 (16) 24.0 (4) 1.92 −1.16, 5.00 0.2123
Wk 53 (n) 18.1 (15) 22.1 (18) 24.4 (5)
change −2.0 −0.3 2.2
95% ci −3.91, −0.16 −2.97, 2.29 −7.11, 11.51
6MWT, m
Bl (n) 459.6 (18) 514.3 (19) 530.7 (5) 53.83 −3.21, 110.86 0.0635
Wk 53 (n) 449.9 (16) 556.8 (18) 555.4 (5)
change −10.4 37.9 24.7
95% ci −58.9, 38.2 2.9, 73.0 −32.0, 81.4
MlhF-Q summary score
Bl (n) 37.0 (20) 21.1 (19) 19.6 (5) 4.27 −5.91, 14.45 0.4003
Wk 53 (n) 34.8 (17) 24.7 (17) 11.0 (5)
change −3.1 2.1 −8.6
95% ci −11.71, 5.47 −3.87, 7.99 −23.9, 6.7
Notes: change is calculated based on mean values. all cis are calculated based on the mean (descriptive or least squares).
Abbreviations: BL, baseline; CI, confidence interval; EOW, every other week; LSM, least squares mean; MLHF-Q, Minnesota Living with Heart Failure Questionnaire; 
6MWT, 6-minute walk test; Peak VO2, maximal oxygen consumption; sD, standard deviation; Wk, week.
weekly group (25%). The difference (95% CI) in the proportion 
of patients who showed an improvement of one class or higher in 
NYHA classification between the 0.2-mg/kg EOW and weekly 
groups was −6.8% (−44.5%, 30.9%). In the 0.4-mg/kg weekly 
group, one patient in Class II (20%) and one patient in Class III 
(20%) at baseline improved to Class I by Week 53.
Regarding renal function, the baseline mean (standard 
deviation [SD]) eGFR was 82.0 mL/min/1.73 m2 (34.1) in 
the 0.2-mg/kg EOW group, 78.1 mL/min/1.73 m2 (33.8) 
in the 0.2-mg/kg weekly group, and 72.1 mL/min/1.73 m2 
(31.2) in the 0.4-mg/kg weekly group (Table 4). The mean 
changes (95% CI) from baseline in eGFR at Week 53 were 
−1.21 mL/min/1.73 m2 (−7.46, 5.05) in the 0.2-mg/kg EOW 
group, −3.32 mL/min/1.73 m2 (−9.63, 2.99) in the 0.2-mg/kg 
weekly group, and −1.68 (−14.00, 10.64) mL/min/1.73 m2 
in the 0.4-mg/kg weekly group. The estimated difference 
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from the statistical model in mean change between the 
0.2-mg/kg groups was not significant (−1.56 [95.005% 
CI: −9.23, 6.12]; unadjusted P-value =0.6830; Table 4). 
A subset analysis of eGFR by CKD stage showed that 
patients with Stage 1A CKD (eGFR $130 mL/min/1.73 m2) 
at baseline had a reduced mean eGFR at Week 53 (mean 
change [95% CI] −24.4 [−82.6, 34.2] in the 0.2-mg/kg 
EOW group and −24.4 [−71.4, 22.6] in the 0.2-mg/kg weekly 
group; Table 5). Patients with all other CKD stages at base-
line remained stable throughout the study.
Due to the high variability of A/Cr data, median values for 
the A/Cr ratio were evaluated (0.2 mg/kg EOW baseline 41.5 
[range 4–2,394], median change by Week 53 −7.0; 0.2 mg/kg 
weekly baseline 40.0 [range 3–1,982], median change by 
Week 53 −6.0; 0.4 mg/kg weekly baseline 250 [range 
81–486], median change by Week 53 −64.0; Table 4). The 
median A/Cr ratio in each 0.2-mg/kg group remained stable 
over the 53 weeks and, based on the statistical model, no sta-
tistically significant difference was found in the change from 
baseline to Week 53 between the two 0.2-mg/kg groups.
Mean baseline plasma Gb
3
 values were only slightly ele-
vated above normal (upper limit of normal 3.9 nmol/mL) in all 
three treatment groups (0.2 mg/kg EOW, mean 6.1 nmol/mL 
[n=20]; 0.2 mg/kg weekly, mean 5.7 [n=19]; 0.4 mg/kg 
weekly, mean 5.3 [n=5]; Table 6). The mean changes (SD) 
from baseline at Week 53 in Gb
3
 were −1.0 nmol/mL (2.3) 
in the 0.2-mg/kg EOW group and −2.1 nmol/mL (4.4) in 
the 0.2-mg/kg weekly group. From the statistical analysis, 
the LSM difference between the two 0.2-mg/kg groups 
was −1.017 nmol/mL [95.005% CI: −2.127, 0.094]; unad-
justed P-value =0.0715). An exploratory analysis of changes 
in Gb
3
 by sex also found no significant mean changes from 
baseline or differences between the 0.2-mg/kg regimens.
safety outcomes
The frequencies of treatment-emergent AEs were similar in 
the three treatment groups (0.2 mg/kg EOW, 95% [n=19]; 
0.2 mg/kg weekly, 89.5% [n=17]; 0.4 mg/kg, 100% [n=5]). 
Infusion-related reactions were mild or moderate and were 
reported in 25% (n=11) of patients overall: 5/20 (25.0%), 
4/19 (21.1%), and 2/5 (40%) patients experienced at least 
one infusion-related AE in the 0.2-mg/kg EOW and weekly 
and the 0.4-mg/kg weekly groups, respectively. No patients 
reported severe or life-threatening, infusion-related AEs. Infu-
sion-related AEs experienced by two or more patients overall 
were tachycardia (4.5% [n=2]), hypotension (4.5% [n=2]), 
and fatigue (9.1% [n=4]). Fewer patients in the 0.2-mg/kg 
weekly group experienced severe or life-threatening AEs 
(21.1% [n=4]) compared with the 0.2-mg/kg EOW group 
(40.0% [n=8]). No severe or life-threatening AEs were 
reported by those in the 0.4-mg/kg group. Furthermore, 
a lower percentage of patients in the 0.2-mg/kg weekly 
group experienced serious adverse events (SAEs) (26.3% 
[n=5]) compared with the EOW group (40.0% [n=8]) or the 
0.4-mg/kg weekly group (40.0% [n=2]). An SAE of hypoten-
sion (also considered an infusion-related AE) was deemed 
possibly related to the study drug and was experienced by 
a patient in the 0.2-mg/kg EOW group; it resolved without 
sequelae. A life-threatening SAE of traumatic hematoma 
was experienced by another patient in the 0.2-mg/kg EOW 
group; this was deemed unrelated to the study drug and 
resolved without sequelae. A further patient in the 0.2-mg/
kg EOW group suffered an SAE of cardiac arrest with a 
fatal outcome, which was also considered unrelated to the 
study drug.
Overall, anti–agalsidase alfa antibodies were detected 
(titers #130) in 11.4% (n=5) of patients: in three patients 
Table 4 changes from baseline to Week 53 in mean egFr and median a/cr ratio
Parameter 0.2 mg/kg  
EOW
0.2 mg/kg  
weekly
0.4 mg/kg  
weekly
0.2 mg/kg weekly minus EOW
LSM difference CI P-value
Mean egFr, ml/min/1.73 m2
Bl (n) 82.0 (20) 78.1 (19) 72.1 (5) −1.56 95.005% ci:  
−9.23, 6.12
Unadjusted 
P=0.6830Wk 53 (n) 78.3 (17) 77.5 (18) 70.4 (5)
change −1.21 −3.32 −1.68
95% ci −7.46, 5.05 −9.63, 2.99 −14.00, 10.64
sD 34.1 33.8 31.2
Mediana a/cr ratio
Bl (n) 41.5 (20) 40.0 (19) 250.0 (5) −134.91 95% ci:  
−482.22, 212.41
P=0.4342
Wk 53 (n) 24.0 (17) 27.0 (17) 151.0 (5)
change −7.0 −6.0 −64.0
95% ci −237.3, 405.2 −219.9, 111.8 −420.3, 311.9
Notes: change is calculated based on mean values. all cis are calculated based on the mean (descriptive or least squares). aMedian values used due to high variability of 
mean values.
Abbreviations: A/Cr, albumin creatinine ratio; BL, baseline; CI, confidence interval; eGFR, estimated glomerular filtration rate; EOW, every other week; LSM, least squares 
mean; sD, standard deviation; Wk, week.
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Table 5 Estimated glomerular filtration rate by CKD stage: mean change from baseline by Week 53
CKD stage 1A (n=3) 1B (n=3) 2 (n=10) 3 (n=3) 4/5 (n=1)
0.2 mg/kg EOW
Mean (sD) egFr at Bl, ml/min/1.73 m2 137.3 (9.6) 108.3 (8.6) 75.6 (6.8) 46.3 (14.3) 8.2 
Mean (95% ci) change from Bl −24.2 (−82.6, 34.2) 1.6 (−35.4, 38.7) 4.5 (−1.2, 10.1) −5.0 (−27.3, 17.2) −1.2 (−7.5, 5.0)
0.2 mg/kg weekly (n=2) (n=5) (n=7) (n=3) (n=2)
Mean (sD) egFr at Bl, ml/min/1.73 m2 142.5 (3.8) 97.5 (7.1) 74.7 (11.2) 47.2 (15.3) 23.4 (7.4)
Mean (95% ci) change from Bl −24.4 (−71.4, 22.6) −4.3 (−21.4, 12.8) −1.2 (−8.4, 5.9) 7.3 (−24.6, 39.2) −2.9 
0.4 mg/kg weekly (n=0) (n=1) (n=3) (n=0) (n=1)
Mean (sD) egFr at Bl, ml/min/1.73 m2 109.9 75.5 (6.9) 23.9
Mean (95% ci) change from Bl −0.4 −2.3 (−37.0, 32.4) −1.0
Notes: cKD stage 1a: $130 ml/min/1.73 m2; 1B: 90 ml/min/1.73 m2 to ,130 ml/min/1.73 m2; 2: 60 ml/min/1.73 m2 to ,90 ml/min/1.73 m2; 3: 30 ml/min/1.73 m2 
to ,60 ml/min/1.73 m2; 4/5: 0 to ,30 ml/min/1.73 m2. change is calculated based on mean values. all cis are calculated based on the mean (descriptive or least squares). 
Abbreviations: BL, baseline; CI, confidence interval; CKD, chronic kidney disease; eGFR, estimated glomerular filtration rate; EOW, every other week; SD, standard 
deviation.
Table 6 changes from baseline to Week 53 in mean plasma gb3
Parameter 0.2 mg/kg EOW  
mean values
0.2 mg/kg weekly  
mean values
0.4 mg/kg weekly  
mean values
0.2 mg/kg weekly minus EOW
LSM difference CI P-value
Plasma gb3, nmol/ml
Bl (n) 6.1 (20) 5.7 (19) 5.3 (5) −1.02 95.005% ci:  
−2.13, 0.09
Unadjusted 
P=0.0715Wk 53 (n) 4.8 (17)a 3.7 (18)b 3.2 (5)
change −1.0 −2.1 −2.1
95% ci −2.21, 0.11 −4.30, 0.04 −3.63, −0.53
Males
Bl (n) 7.2 (14) 7.7 (10) 6.8 (2) n/a n/a n/a
Wk 53 (n) 5.5 (11) 4.1 (10) 4.0 (2)
change −1.6 −3.6 −2.8
95% ci −3.36, 0.13 −7.53, 0.32 −13.33, 7.77
Females
Bl (n) 3.5 (6) 3.3 (9) 4.3 (3) n/a n/a n/a
Wk 53 (n) 3.5 (6) 3.1 (8) 2.7 (3)
change −0.01 −0.29 −1.6
95% ci −0.95, 0.93 −0.93, 0.34 −4.75, 1.54
Notes: change is calculated based on mean values; all cis are calculated based on the mean (descriptive or least squares). aThree patients discontinued before week 53. 
bOne patient discontinued before week 53.
Abbreviations: BL, baseline; CI, confidence interval; Gb3, globotriaosylceramide; eOW, every other week; lsM, least squares mean; Wk, week; n/a, not applicable.
from the 0.2-mg/kg EOW group (1 immunoglobulin G 
[IgG], 1 IgM, and 1 IgG/IgM) and two from the 0.2-mg/kg 
weekly group (1 IgG, 1 IgM; none were detected in the 
0.4-mg/kg weekly group). Neutralizing antibodies were 
detected in 6.8% (n=3) patients: in two patients from the 
0.2-mg/kg EOW group (1 IgG, 1 IgG/IgM) and one from 
the 0.2-mg/kg weekly group (1 IgG). Seroconversion was 
noted in three patients in the 0.2-mg/kg EOW group (two 
persistently positive for IgG or IgG/IgM and neutralizing 
antibodies; one transiently positive for IgM but no neu-
tralizing antibodies) and in two patients in the 0.2-mg/kg 
weekly group (one persistently positive for IgG and neu-
tralizing antibodies, one persistently positive for IgM but 
no neutralizing antibodies). Infusion-related reactions did 
not appear to be correlated with antibody or neutralizing 
antibody status.
Concomitant medication usage and changes in laboratory 
parameters, vital signs, and electrocardiogram results were 
also monitored as part of the safety profile of each patient. 
No clinically meaningful trends over time were observed, 
and the results from these measures were consistent between 
treatment groups.
Discussion
This study reports the efficacy and safety outcomes of two 
potential alternative treatment regimens of agalsidase alfa, 
alongside the approved dose of 0.2 mg/kg EOW, in adult 
patients with FD and LVH. The approved dose has previously 
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been shown to improve or stabilize the progression of clinical 
manifestations of FD,14,15,17,18 and the results herein indicate 
that the alternative regimens of 0.2 mg/kg and 0.4 mg/kg 
weekly also slowed the progression of some FD manifesta-
tions. The analysis of 0.4 mg/kg weekly was exploratory; 
statistical comparisons were only made between the two 
0.2-mg/kg regimens.
Presence of LVH at baseline was an inclusion criterion 
of the study. Patients with advanced cardiomyopathy at 
baseline might not be expected to show great improvement 
during enzyme replacement therapy,30 although slowing of 
disease progression or disease stabilization would still be an 
important outcome. Consistent with this, LVMI remained 
stable over the 53-week study period and did not significantly 
differ between the 0.2-mg/kg EOW and weekly regimens. 
An improvement or stabilization in cardiac outcomes after 
treatment with the approved dose of 0.2 mg/kg agalsidase 
alfa EOW has previously been demonstrated.17,20 The appar-
ent stabilization in cardiac status herein also seemed to be 
reflected by an improvement in NYHA classification for two 
patients in each of the 0.2-mg/kg treatment groups.
Regarding exercise tolerance, no universally accepted ref-
erence values exist as yet for the 6MWT, but one multicenter 
study of 444 healthy adults showed an overall mean (SD; range) 
distance walked of 571 (90; 380–782) m,31 and a single-center 
study on 102 healthy adults an overall mean (SD; range) dis-
tance of 614 (56; 459–738) m.32 The mean distances walked 
at baseline in the 0.2-mg/kg EOW and weekly groups of the 
present study were similar to these results in healthy adults, 
potentially indicating that there has not been significant impact 
from the disease on the mean distance walked and therefore 
clinically meaningful improvements would not be expected 
as a result of treatment. For peak VO
2
, a slight reduction was 
observed in the group receiving 0.2 mg/kg EOW, although 
the interpretation of peak VO
2
 data is confounded by missing 
baseline data and the fact that information was lacking on 
whether the patients had exercised to their maximum capacity. 
However, no significant differences in change from baseline 
were observed for peak VO
2
 between the two 0.2-mg/kg 
groups, and quality of life, as assessed by Minnesota Living 
with Heart Failure Questionnaire scores, also remained stable 
for both 0.2-mg/kg groups. Overall, the results of the current 
study do not indicate any additional cardiac benefits from 
increasing the dose to 0.2 mg/kg every week.
The patients were not selected or stratified based on 
baseline eGFR values or their renal status; these showed con-
siderable variation, but changes within the 0.2-mg/kg EOW 
and weekly groups by study end were minimal and did not 
significantly differ between the two groups. When analyzed 
by CKD stage, reductions in mean eGFR in patients with 
hyperfiltration (Stage 1A, $130 mL/min/1.73 m2; 0.2-mg/kg 
groups only) occurred by Week 13 and remained stable 
until the end of the study, indicating possible normalization 
of renal function in these patients. The eGFR of patients 
in the 0.2-mg/kg groups with all other CKD stages was 
maintained throughout, thus indicating that renal function 
remained stable in these treatment groups. The numbers 
in this CKD subset analysis were small; thus, the results 
should be interpreted with care. However, the apparent 
stability demonstrated in renal function was mirrored by the 
A/Cr data, which although highly variable, also showed no 
significant changes by Week 53 or between the 0.2-mg/kg 
groups in median values.
Mean baseline plasma Gb
3
 values were only slightly ele-
vated and did not significantly differ in changes from baseline 
between the two 0.2-mg/kg treatment groups. Males typically 
exhibit higher baseline plasma Gb
3
 values than females; thus, 
their expected reductions posttreatment are greater. In this 
study, the slightly greater decrease observed by Week 53 in the 
0.2-mg/kg weekly group is difficult to interpret because mean 
baseline plasma Gb
3
 levels in both groups were relatively low, 
and numbers of males and females in each group differed. 
Although not analyzed in this study, globotriaosylsphingosine 
(lysoGb
3
), a deacylated Gb
3
, has been introduced as a promis-
ing new biomarker for monitoring the course of FD.33 It is 
reported to have greater sensitivity and reliability than plasma 
or urine Gb
3
;34 thus, future reports analyzing LysoGb
3
 in FD, 
rather than Gb
3
, are likely to be of interest.
This study was not powered to detect differences in sec-
ondary endpoints between the treatment groups, and as such, 
these results should be interpreted with caution; however, 
they are consistent with the primary LVMI endpoint in that 
no significant changes were observed from baseline by the 
end of the study within or between the 0.2-mg/kg EOW and 
weekly groups.
Agalsidase alfa was generally found to be safe and well 
tolerated. The percentages of patients who experienced 
AEs such as infusion-related reactions and who developed 
anti–agalsidase alfa antibodies were similar to previous 
experience.15 The results suggest that fewer patients in 
the 0.2-mg/kg weekly group experienced severe or life-
threatening AEs or SAEs, and increasing dosing frequency 
from EOW to weekly did not seem to result in more patients 
developing antibodies nor changes in the safety profile. Fur-
thermore, there was no apparent impact on treatment effect 
or safety from being anti–agalsidase alfa positive.
Evaluation of the 0.4-mg/kg group was exploratory only 
and not planned for comparison with the two 0.2-mg/kg 
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Furthermore, the exploratory evaluation of 0.4 mg/kg 
weekly showed no significant deviation from these results. 
The study data herein support the current approved dosing 
regimen.
Acknowledgments
The authors thank all the patients who participated in this 
study, which was funded by Shire. Medical writing assistance 
(supported financially by Shire) was provided by Annie Rowe 
and Tina Rose (Excel Scientific Solutions, Horsham, UK) 
during the preparation of the manuscript.
Disclosure
LG was the principal investigator for the current study with 
Shire and has received travel funding from Genzyme and 
Shire. OG has received research support from Actelion, 
Amicus, Genzyme Corp, Pfizer-Protalix Biotherapeutics, 
and Shire; payments for consultancy from Actelion, Pfizer-
Protalix Biotherapeutics, and Shire; and payments for speaker 
bureaus from Actelion, Genzyme, and Shire. MH has received 
consultancy payments from Shire; his institution has received 
grant support from Protalix, Amicus, and Genzyme. IK has 
received speaking fees and travel funding from Genzyme 
and Shire. AL is a member of the Fabry Registry Board of 
Advisors, which is sponsored by Genzyme. KN has received 
research support and travel grants from Amicus, Genzyme, 
and Shire and speaker honoraria from Genzyme and Shire. 
RS was the principal investigator for a study with Shire, has 
received travel funding from Shire, and has attended Shire’s 
Fabry Advisory Board meetings. BV has received speak-
ing fees and travel grants from Genzyme and Shire and is a 
member of the Fabry Registry Board of Advisors, which is 
sponsored by Genzyme. PC and AW are employees of, and 
hold stock options in, Shire. MK, JK, JM, and DGR declare 
no conflicts of interest in this work. The authors report no 
other conflicts of interest in this work.
References
1. Online Mendelian Inheritance in Man OMIM®. Fabry Disease. 
2012–13. Available from: http://www.omim.org/entry/301500. Accessed 
December 4, 2014.
2. Garman SC, Garboczi DN. The molecular defect leading to Fabry dis-
ease: structure of human alpha-galactosidase. J Mol Biol. 2004;337(2): 
319–335.
3. MacDermot KD, Holmes A, Miners AH. Natural history of Fabry dis-
ease in affected males and obligate carrier females. J Inherit Metab Dis. 
2001;24(suppl 2):13–14. [discussion 11–12].
4. MacDermot KD, Holmes A, Miners AH. Anderson-Fabry disease: clini-
cal manifestations and impact of disease in a cohort of 98 hemizygous 
males. J Med Genet. 2001;38(11):750–760.
5. Mehta A, Ricci R, Widmer U, et al. Fabry disease defined: baseline 
clinical manifestations of 366 patients in the Fabry Outcome Survey. 
Eur J Clin Invest. 2004;34(3):236–242.
treatment groups, but the efficacy and safety results for this 
group were generally consistent with those of the 0.2-mg/kg 
groups. No new safety concerns were introduced by this 
increased dosage.
As is often the case in rare disease studies, the total 
number of patients in this study was small, especially given 
the echocardiography-based primary endpoint; this fact, 
along with the relatively short-term study, limits the conclu-
sions that can be drawn. A longer period of follow-up may 
be needed to confirm the apparent stabilization in cardiac 
status that was observed. To evaluate left ventricular mass, 
we chose echocardiography as a standardized, readily avail-
able, reproducible, and noninvasive technique.35 However, 
the limitation of echocardiography is the inability to detect 
fibrosis. Gadolinium-enhanced cardiovascular magnetic 
resonance can detect fibrosis, but it has other limitations 
(eg, toxicity in advanced renal failure, the impossibility of 
examining patients with implanted ferromagnetic materials, 
and less readily available technology).36
FD manifestations have been reported to occur later, 
progress at a slower rate, and vary in degree of severity in 
females compared with males.10,37–39 Thus, the greater number 
of male patients and patients .45 years old, plus the inclu-
sion of patients with NYHA Class III in the 0.2-mg/kg EOW 
group, could suggest a somewhat greater disease burden at 
the start in this group compared with the 0.2-mg/kg weekly 
group. However, these baseline differences were not statisti-
cally significant; furthermore, mean age and LVMI did not 
significantly differ between the two groups at baseline.
This study was not designed to assess genotype; the lack 
of mutation analyses for all patients meant that the propor-
tion of patients with later onset cardiac variant FD, and thus 
potential differences in treatment efficacy with agalsidase 
alfa for classic and cardiac variant FD, is unknown.40 Also, 
although further detailed information on antiproteinuric 
therapy with angiotensin-converting enzyme inhibitors or 
angiotensin receptor blockers throughout the study might 
be useful for evaluating proteinuria and albuminuria, the 
variability found in baseline A/Cr ratios may still hamper 
interpretation. Furthermore, the inclusion of patients with 
different stages of CKD, including some with end-stage 
renal disease, limits the extent of renal conclusions that can 
be drawn for the overall study population.
Conclusion
Overall, this study found no differences in efficacy outcomes 
or safety when the frequency of agalsidase alfa enzyme 
replacement therapy was increased from the approved dose 
of 0.2 mg/kg EOW to the same dose administered weekly. 
 
D
ru
g 
D
es
ig
n,
 D
ev
el
op
m
en
t a
nd
 T
he
ra
py
 d
ow
nl
oa
de
d 
fr
om
 h
ttp
s:
//w
w
w
.d
ov
ep
re
ss
.c
om
/ b
y 
95
.1
74
.4
5.
14
5 
on
 2
6-
M
ar
-2
02
0
F
or
 p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
Drug Design, Development and Therapy
Publish your work in this journal
Submit your manuscript here: http://www.dovepress.com/drug-design-development-and-therapy-journal
Drug Design, Development and Therapy is an international, peer-
reviewed open-access journal that spans the spectrum of drug design 
and development through to clinical applications. Clinical outcomes, 
patient safety, and programs for the development and effective, safe, 
and sustained use of medicines are a feature of the journal, which 
has also been accepted for indexing on PubMed Central. The manu-
script management system is completely online and includes a very 
quick and fair peer-review system, which is all easy to use. Visit 
http://www.dovepress.com/testimonials.php to read real quotes from 
published authors.
Drug Design, Development and Therapy 2015:9submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
Dovepress
3444
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